Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2021

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of September 30, 2021 and December 31, 2020 were as follows:


	September 30, 2021		December 31, 2020
Accrued compensation expenses	$	252,117	$	317,068
Accrued research and development		314,984		89,156
Accrued professional fees		133,194		49,707
Other accounts payable and accrued expenses		12,142		—
Total	$	712,437	$	455,931